secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628908-24-000112
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q3 revenue rises 21.6% to $621M, net loss $31.2M; EBITDA miss due to $42M medical cost spike
--------------------------------------------------------------------------------

- Revenue $621.4M, up 21.6% YoY; net loss $(31.2)M vs $(33.2)M prior year.
- Adjusted EBITDA $31.8M (5.1% margin), down from $48.7M (9.5%) YoY.
- Medical costs exceeded expectations by $42M: $24M prior-period claims, $18M oncology spike.
- Company revises 2024 Adjusted EBITDA guidance; reiterates long-term growth targets.
- Record six new contracts signed, including oncology Performance Suite with top-5 payer (200k members).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/0001628908-24-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890824000112/evh-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628908-24-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer